Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701130 | European Journal of Surgical Oncology (EJSO) | 2016 | 8 Pages |
Abstract
Aside from well-known clinical-pathologic prognostic factors in H&N cancers, HRQL assessment, both prior to and after treatment, provides significant prognostic information and should be measured. Design of therapeutic clinical trials in patients with H&N cancers should consider these novel prognostic factors.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J.F. Carrillo, L.C. Carrillo, M.C. Ramirez-Ortega, F.J. Ochoa-Carrillo, L.F. Oñate-Ocaña,